Skip to main content
REGN
NASDAQ Life Sciences

FDA 批准 EYLEA HD 延长给药间隔最长可达 5 个月，首款且唯一一款具有最宽间隔的抗 VEGF 药物

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$747
Mkt Cap
$77.616B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

Regeneron 制药公司宣布，其 EYLEA HD® (aflibercept) 已获得 FDA 批准，适用于湿性年龄相关性黄斑变性 (wAMD) 和糖尿病黄斑水肿 (DME) 患者的延长给药间隔，最长可达 20 周（5 个月）。这使得 EYLEA HD 成为首款且唯一一款具有此类延长给药间隔的注射性抗 VEGF 治疗，通过减少治疗负担为成功响应治疗一年以上的患者提供了显著的竞争优势。该批准基于关键 PULSAR 和 PHOTON 试验的 96 周数据，证明了持续的疗效和安全性。该关键收入驱动因素的监管里程碑预计将增强 EYLEA HD 的市场地位和患者依从性，对雷金纳的未来销售和竞争格局产生积极影响。交易者将关注市场接受度和竞争对手的反应。

在该公告发布时，REGN的交易价格为$747.00，交易所为NASDAQ，所属行业为Life Sciences，市值约为$776.2亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article